The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of Novartis' Ultibro Breezhaler, or QVA149, as a treatment for chronic obstructive pulmonary disease. The once-daily drug is a combination of long-acting beta2-adrenergic agonist indacaterol and long-acting muscarinic antagonist glycopyrronium.
EU panel supports approval of Novartis' COPD drug
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||